These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20400095)

  • 21. Efficacy and tolerability of initial therapy with single-pill combination telmisartan/hydrochlorothiazide 80/25 mg in patients with grade 2 or 3 hypertension: a multinational, randomized, double-blind, active-controlled trial.
    Zhu DL; Bays H; Gao P; Mattheus M; Voelker B; Ruilope LM
    Clin Ther; 2012 Jul; 34(7):1613-24. PubMed ID: 22717420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: results from the EPATH randomized, placebo-controlled trial.
    Tomaschitz A; Verheyen N; Meinitzer A; Pieske B; Belyavskiy E; Brussee H; Haas J; März W; Pieske-Kraigher E; Verheyen S; Ofner-Ziegenfuss L; Hartaigh BÓ; Schwetz V; Aberer F; Grübler M; Lang F; Alesutan I; Voelkl J; Gaksch M; Horina JH; Dimai HP; Rus-Machan J; Stiegler C; Ritz E; Fahrleitner-Pammer A; Pilz S
    J Hypertens; 2016 Jul; 34(7):1347-56. PubMed ID: 27065001
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension.
    Karns AD; Bral JM; Hartman D; Peppard T; Schumacher C
    J Clin Hypertens (Greenwich); 2013 Mar; 15(3):186-92. PubMed ID: 23458591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy?
    Prisant LM; Krum H; Roniker B; Krause SL; Fakouhi K; He W
    J Clin Pharmacol; 2003 Nov; 43(11):1203-10. PubMed ID: 14551174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nebivolol monotherapy for patients with systolic stage II hypertension: results of a randomized, placebo-controlled trial.
    Lewin A; Punzi H; Luo X; Stapff M
    Clin Ther; 2013 Feb; 35(2):142-52. PubMed ID: 23332366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension.
    Burgess ED; Lacourcière Y; Ruilope-Urioste LM; Oparil S; Kleiman JH; Krause S; Roniker B; Maurath C
    Clin Ther; 2003 Sep; 25(9):2388-404. PubMed ID: 14604739
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of eplerenone on heart and kidney in two-kidney, one-clip rats.
    Hao L; Kanno Y; Fukushima R; Watanabe Y; Ishida Y; Suzuki H
    Am J Nephrol; 2004; 24(1):54-60. PubMed ID: 14707436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determinants of blood pressure reduction by eplerenone in uncontrolled hypertension.
    Jansen PM; Frenkel WJ; van den Born BJ; de Bruijne EL; Deinum J; Kerstens MN; Arnoldus JH; Woittiez AJ; Wijbenga JA; Zietse R; Danser AH; van den Meiracker AH
    J Hypertens; 2013 Feb; 31(2):404-13. PubMed ID: 23249826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
    Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
    Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease.
    Pitt B; Filippatos G; Gheorghiade M; Kober L; Krum H; Ponikowski P; Nowack C; Kolkhof P; Kim SY; Zannad F
    Eur J Heart Fail; 2012 Jun; 14(6):668-75. PubMed ID: 22562554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
    Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A double-blind, dose-response study of losartan in hypertensive children.
    Shahinfar S; Cano F; Soffer BA; Ahmed T; Santoro EP; Zhang Z; Gleim G; Miller K; Vogt B; Blumer J; Briazgounov I
    Am J Hypertens; 2005 Feb; 18(2 Pt 1):183-90. PubMed ID: 15752945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
    Pitt B; Remme W; Zannad F; Neaton J; Martinez F; Roniker B; Bittman R; Hurley S; Kleiman J; Gatlin M;
    N Engl J Med; 2003 Apr; 348(14):1309-21. PubMed ID: 12668699
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study.
    Krum H; Shi H; Pitt B; McMurray J; Swedberg K; van Veldhuisen DJ; Vincent J; Pocock S; Zannad F;
    Circ Heart Fail; 2013 Jul; 6(4):711-8. PubMed ID: 23625945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial.
    Lacourcière Y; Poirier L; Hebert D; Assouline L; Stolt P; Rehel B; Khder Y
    Clin Ther; 2005 Jul; 27(7):1013-21. PubMed ID: 16154480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mineralocorticoid Receptor Activation Contributes to the Supine Hypertension of Autonomic Failure.
    Arnold AC; Okamoto LE; Gamboa A; Black BK; Raj SR; Elijovich F; Robertson D; Shibao CA; Biaggioni I
    Hypertension; 2016 Feb; 67(2):424-9. PubMed ID: 26644241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria.
    Ando K; Ohtsu H; Arakawa Y; Kubota K; Yamaguchi T; Nagase M; Yamada A; Fujita T;
    Hypertens Res; 2010 Jun; 33(6):616-21. PubMed ID: 20379190
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses.
    Fernet M; Beckerman B; Abreu P; Lins K; Vincent J; Burgess E
    Vasc Health Risk Manag; 2018; 14():233-246. PubMed ID: 30275698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis.
    Stewart RA; Kerr AJ; Cowan BR; Young AA; Occleshaw C; Richards AM; Edwards C; Whalley GA; Freidlander D; Williams M; Doughty RN; Zeng I; White HD;
    Am Heart J; 2008 Aug; 156(2):348-55. PubMed ID: 18657667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.